Skip to main content

Peer Review reports

From: Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion

Original Submission
17 Apr 2019 Submitted Original manuscript
1 May 2019 Reviewed Reviewer Report - Shile Huang
13 May 2019 Reviewed Reviewer Report - Xuerong Wang
5 Aug 2019 Author responded Author comments - Eric Kauffman
Resubmission - Version 2
5 Aug 2019 Submitted Manuscript version 2
6 Aug 2019 Reviewed Reviewer Report - Shile Huang
8 Aug 2019 Reviewed Reviewer Report - Xuerong Wang
12 Aug 2019 Author responded Author comments - Eric Kauffman
Resubmission - Version 3
12 Aug 2019 Submitted Manuscript version 3
24 Aug 2019 Author responded Author comments - Eric Kauffman
Resubmission - Version 4
24 Aug 2019 Submitted Manuscript version 4
Publishing
26 Aug 2019 Editorially accepted
13 Sep 2019 Article published 10.1186/s12885-019-6096-0

You can find further information about peer review here.

Back to article page